CSCI

COSCIENS Biopharma Inc. Common Stock
CSCI
Market cap $11.5M

3.70 USD

+0.00

0%

At close Oct 4, 4:00 PM EDT

1 day

0.00%

5 days

-2.63%

1 month

-7.50%

3 months

-29.52%

6 months

-55.10%

Year to date

-50.80%

1 year

-54.88%

5 years

-96.24%

About: Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

9% more funds holding

Funds holding: 11 [Q1] → 12 (+1) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

21% less capital invested

Capital invested by funds: $141K [Q1] → $112K (-$29K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CSCI.

See Analyst Rankings

Financial journalist opinion

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, announced the appointment of Pierre Labbé to its board of directors and as Chair of the Company's Audit Committee, effective today, to fill the vacancy created by the resignation of Dennis Turpin, also effective today.

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided an update on the progress of its merger integration with Ceapro Inc. (“Ceapro”), including planned changes to its management team and advancements across its current business.

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of macimorelin confirmed in the pediatric population TORONTO, ONTARIO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the top-line results of its Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency ("CGHD"). While top-line data show that macimorelin repeatedly demonstrated its capacity to stimulate growth hormone release as required to perform a growth hormone stimulation test, the primary efficacy endpoint for the DETECT-trial has not been met according to the definitions in the study protocol.

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™